Lempicki RA - Search Results

1

Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Rasimas J, Katsounas A, Raza H, Murphy AA, Yang J, Lempicki RA, Osinusi A, Masur H, Polis M, Kottilil S, Rosenstein D. Rasimas J, et al. Among authors: lempicki ra. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):273-81. doi: 10.1097/QAI.0b013e31824c17c4. J Acquir Immune Defic Syndr. 2012. PMID: 22728749 Free PMC article.

2

Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).

Wu L, Kottilil S, Lempicki R, Yang J, McLaughlin M, Hu Z, Koratich C, Reitano KN, Rehm CA, Masur H, Wood B, Kleiner DE, Polis MA. Wu L, et al. AIDS Res Hum Retroviruses. 2006 Nov;22(11):1091-8. doi: 10.1089/aid.2006.22.1091. AIDS Res Hum Retroviruses. 2006. PMID: 17147494 Clinical Trial.

3

Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.

Osinusi A, Bon D, Nelson A, Lee YJ, Poonia S, Shivakumar B, Cai SY, Wood B, Haagmans B, Lempicki R, Herrmann E, Sneller M, Polis M, Masur H, Kottilil S. Osinusi A, et al. J Med Virol. 2014 Feb;86(2):177-85. doi: 10.1002/jmv.23773. Epub 2013 Oct 26. J Med Virol. 2014. PMID: 24166150

4

Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients.

Nussenblatt V, McLaughlin M, Rehm CA, Lempicki RA, Brann T, Yang J, Proschan M, Highbarger HC, Dewar RL, Imamichi T, Koratich C, Neumann AU, Masur H, Polis MA, Kottilil S. Nussenblatt V, et al. Among authors: lempicki ra. AIDS Res Hum Retroviruses. 2007 Nov;23(11):1354-9. doi: 10.1089/aid.2007.0091. AIDS Res Hum Retroviruses. 2007. PMID: 18184077

5

Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV.

Allison RD, Katsounas A, Koziol DE, Kleiner DE, Alter HJ, Lempicki RA, Wood B, Yang J, Fullmer B, Cortez KJ, Polis MA, Kottilil S. Allison RD, et al. Among authors: lempicki ra. J Infect Dis. 2009 Aug 15;200(4):619-23. doi: 10.1086/600107. J Infect Dis. 2009. PMID: 19594300 Free PMC article.

6

Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia.

Kottilil S, Jackson JO, Reitano KN, O'Shea MA, Roby G, Lloyd M, Yang J, Hallahan CW, Rehm CA, Arthos J, Lempicki R, Fauci AS. Kottilil S, et al. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):151-9. doi: 10.1097/QAI.0b013e3180dc9909. J Acquir Immune Defic Syndr. 2007. PMID: 17558334

7

Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells.

Kottilil S, Yan MY, Reitano KN, Zhang X, Lempicki R, Roby G, Daucher M, Yang J, Cortez KJ, Ghany M, Polis MA, Fauci AS. Kottilil S, et al. Hepatology. 2009 Jul;50(1):34-45. doi: 10.1002/hep.23055. Hepatology. 2009. PMID: 19551908 Free PMC article.

8

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S. Naggie S, et al. Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2. Hepatology. 2012. PMID: 22331604 Free PMC article. Clinical Trial.

9

Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach.

Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, Mican JM, Suffredini A, Masur H, Polis MA, Kottilil S. Suzman DL, et al. Among authors: lempicki ra. AIDS. 2008 Jul 31;22(12):1433-9. doi: 10.1097/QAD.0b013e328304dfe7. AIDS. 2008. PMID: 18614866 Free PMC article.

10

Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.

Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, Chung TL, Wood BJ, Haagmans BL, Kottilil S, Polis MA. Murphy AA, et al. Among authors: lempicki ra. AIDS. 2011 Jun 1;25(9):1179-87. doi: 10.1097/QAD.0b013e3283471d53. AIDS. 2011. PMID: 21593619 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page